FORM PTO-1449 U.S. DEPARTMENT OF COMMERCE (MODIFIED) U.S. PATENT AND TRADEMARK OFFICE	ATTY. DOCKET NO. 00-149	SER_NO. 09/8 15,700 III
INFORMATION DISCLOSURE STATEMENT BY APPLICANT	APPLICANT WONG et al.	1 5 201 TER 160
(37 CFR 1.98(b))	FILING DATE March 16, 2001	1646 B

## **U.S. PATENT DOCUMENTS**

Examiner Initial	Cite No.	Patent Number	Issue Patentee Date	Class/ Subclass	Fling Date
					JUL 1
					TER 1.5
					160
	<u> </u>	ODEICN DATENT	OP DUBLISHED EODEIGN DAT	ENT ADDI IOATIC	တ္ (

Examiner Cito Initjal No		Publication Date	Country or Patent Office	Class/ Subclass	Translation Yes/No
WAL	WO 01/62930 A1	8/30/01	WO		
			,		

## **OTHER DOCUMENTS** (Including Author, Title, Date, Relevant Pages, Place of Publication)

Examiner Initial	Cite No.	
_KOL		Ellerby, H. M. et al.; Anti-Cancer Activity of Targeted Pro-Apoptotic Peptides; Nature Medicine, Vol. 5, No. 9, pp. 1032-1038; 1999.

EXAMINER		DATE CONSIDERED
farm d.	Ganella	11/102

EXAMINER: Initial citation considered. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.